- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
Patent holdings for IPC class A61K 31/5377
Total number of patents in this class: 10979
10-year publication summary
|
957
|
1025
|
967
|
929
|
902
|
910
|
967
|
978
|
772
|
212
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 11238 |
239 |
| Takeda Pharmaceutical Company Limited | 2961 |
130 |
| Bristol-myers Squibb Company | 5080 |
129 |
| Epizyme, Inc. | 383 |
120 |
| Boehringer Ingelheim International GmbH | 4629 |
111 |
| Merck Sharp & Dohme LLC | 3689 |
111 |
| Merck Patent GmbH | 5909 |
103 |
| Taisho Pharmaceutical Co., Ltd. | 844 |
103 |
| Gilead Sciences, Inc. | 1879 |
100 |
| F. Hoffmann-La Roche AG | 7958 |
97 |
| Astellas Pharma Inc. | 1145 |
94 |
| Celgene Corporation | 1412 |
92 |
| Shionogi & Co., Ltd. | 914 |
90 |
| Janssen Pharmaceutica N.V. | 3839 |
84 |
| Bayer Pharma AG | 1096 |
84 |
| Abbvie Inc. | 1808 |
72 |
| Chugai Seiyaku Kabushiki Kaisha | 1259 |
69 |
| Genentech, Inc. | 3742 |
67 |
| AstraZeneca AB | 3042 |
64 |
| Daiichi Sankyo Company, Limited | 1829 |
64 |
| Other owners | 8956 |